Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 7/20 | 0.41 |
| ▸ | AKT2 | P31751 | 5/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904781 | 0.94 | AKT1 (0.41) | AKT1AKT2BRD4PDE2ACNR1 | |
| SCHEMBL1901181 | 0.84 | AKT1 (0.48) | AKT1AKT2BRD4 | |
| SCHEMBL1904773 | 0.81 | AKT1 (0.36) | AKT1AKT2BRD4PDE2A | |
| SCHEMBL1534659 | 0.81 | AKT1 (0.41) | AKT1AKT2LMNAALDH1A1 | |
| SCHEMBL14118831 | 0.81 | AKT1 (0.46) | AKT1AKT2 | |
| SCHEMBL1908238 | 0.81 | AKT1 (0.43) | AKT1AKT2CNR1CNR2KIT | |
| SCHEMBL1905277 | 0.81 | BRD4 (0.38) | AKT1AKT2BRD4NR4A2PDE2A | |
| SCHEMBL1534577 | 0.79 | AKT1 (0.41) | AKT1AKT2PDE2ACNR1CNR2 | |
| SCHEMBL14118644 | 0.79 | AKT1 (0.42) | AKT1AKT2BRD4PDE2ACNR1 | |
| SCHEMBL1903507 | 0.78 | AKT1 (0.33) | AKT1AKT2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885BRD4 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.